Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig in Japanese RRMM
NCT05286229Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Number of Dose-Limiting Toxicities at 12 months and Number of Participants with Adverse Events at 24 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05286229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286229.